By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

OhhMed Medical Ltd., a pioneering medical technology firm specialising in male urology, today announced the initiation of a ...

The optimal strategy for treating newly diagnosed high-risk prostate cancer remains unclear. More specifically, do these patients benefit more from radical prostatectomy or a radiotherapy-based ...

A prostatectomy is surgery to partially or completely remove the prostate gland to treat conditions such as prostate cancer or benign prostatic hyperplasia (BPH). A radical prostatectomy is the ...

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis ...